Atorvastatin, ,

Small molecule

SShaheed Benazir Bhutto University Sheringal Dir Upper

Atorvastatin, , is one of 20 small molecule programs targeting Long COVID-19. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long COVID-19Active, not recruiting

Long COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Long COVID-19

#DrugCompanyPhaseTrials

Norvir

Corlanor

Epidiolex

Revia

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—6

Celebrex

PPhiladelphia Eye Associates

Approved

—7

Rapamune

PPrism Pharmaceuticals

Approved

—8

Trental

VValidus Pharmaceuticals

Approved

—9

Lithobid

SSolvay Pharmaceuticals

Olumiant

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Statins

NCT07378293

Phase 1Not yet recruiting

Cardiovascular

NCT07389304

Clinical

Trials by Indication[1]

Statins1 trial

Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers

Not yet recruiting·SShaheed Benazir Bhutto University Sheringal Dir Upper·Phase 1·NCT07378293·100 enrolled

Long COVID-191 trial

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

Not yet recruiting·HHealthBio, Inc.·Phase 2/3·NCT06974084·252 enrolled

Cardiovascular1 trial

[Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]

Not yet recruiting·SShaheed Benazir Bhutto University Sheringal Dir Upper·Phase 1·NCT07389304·100 enrolled

Unspecified1 trial

Korean AMADEUS Study

Unknown status·TThe Catholic University of Korea·Phase 4·NCT01239849·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Atorvastatin, ,. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atorvastatin, , compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atorvastatin, ,. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shaheed Benazir Bhutto University Sheringal Dir Upper company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SShaheed Benazir Bhutto University Sheringal Dir Upper

Atorvastatin, ,

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Statins1 trial

Long COVID-191 trial

Cardiovascular1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News